Andrew E. Hendifar, MD

Articles by Andrew E. Hendifar, MD

Theranostics and Management of NETS Going Forward

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

January 14th 2026

Discover the future of cancer treatment with innovative therapies and groundbreaking research in radiopharmaceuticals and theranostics.

CAR-T and Radioligand Therapies for Treatment of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

January 7th 2026

Experts discuss the promising future of CAR-T therapy and radioligand treatments for neuroendocrine tumors, highlighting new trials and potential breakthroughs.

Sequencing and Place of Cabozantinib in NETS Treatment Algorithm

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

January 7th 2026

Experts discuss the challenges of sequencing treatments like cabozantinib and managing side effects in patients with metastatic disease.

CABINET Study and Cabozantinib for Treatment of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 23rd 2025

Dr. Chauhan discusses the groundbreaking CABINET trial, revealing its impact on treating neuroendocrine tumors and the future of oncology research.

Patient with NETS Post PRRT in Second-Line

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 23rd 2025

Experts discuss treatment options for a young patient with pancreatic neuroendocrine tumor and liver metastases, focusing on targeted therapies.

Treatment Options for High Grade (Grade 3) NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 16th 2025

Doctor Hendifer discusses the diverse therapies for neuroendocrine neoplasms, emphasizing individualized treatment based on patient needs and disease characteristics.

Sequencing of Systemic NETS Treatments

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 16th 2025

Experts discuss advanced treatment options for neuroendocrine tumors, highlighting PRRT, mTOR inhibitors, and emerging therapies for improved patient outcomes.

Inadequate Response and Second-Line Treatment of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 9th 2025

Oncology treatment decisions hinge on tumor biology and patient factors, emphasizing a multidisciplinary approach for optimal care.

Site of Origin and Treatment of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 9th 2025

Experts discuss treatment strategies for neuroendocrine tumors, emphasizing personalized approaches based on tumor grade, symptoms, and patient health.

First-Line Treatment and Standard of Care for NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 2nd 2025

Explore the complexities of treating neuroendocrine tumors, focusing on patient-specific strategies and the role of somatostatin analogs.

Prognostic Factors for Neuroendocrine Tumors

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 2nd 2025

Experts discuss key factors influencing disease prognosis, emphasizing differentiation, growth pace, and disease burden in treatment decisions.

Role of Biomarkers in Diagnosis and Management of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

November 21st 2025

Experts discuss the evolution of neuroendocrine tumor classification, highlighting its clinical implications and the importance of standardized treatment approaches.

Early Diagnosis of Neuroendocrine Tumors

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

November 21st 2025

Experts discuss the evolution of neuroendocrine tumor classification, highlighting its impact on diagnosis, treatment, and clinical implications.

Imaging Modalities for Neuroendocrine Tumors

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

November 14th 2025

Imaging Modalities for Neuroendocrine Tumors

Classification of Neuroendocrine Tumors

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

November 14th 2025

Classification of Neuroendocrine Tumors

Dr. Hendifar Discusses the Future Treatment of NETs

ByAndrew E. Hendifar, MD

February 12th 2018

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the future treatment landscape for patients with neuroendocrine tumors (NETs).

Dr. Hendifar Discusses a 92-Gene Assay of NETs

ByAndrew E. Hendifar, MD

November 28th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

Dr. Hendifar on the Current Treatment Landscape in Pancreas Cancer

ByAndrew E. Hendifar, MD

July 14th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the current treatment landscape in pancreas cancer.

Dr. Hendifar on the HALO-202 Study in Metastatic Pancreatic Ductal Adenocarcinoma

ByAndrew E. Hendifar, MD

June 29th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.